Exelixis (NASDAQ:EXEL) Lowered to "Hold" Rating by Zacks Research

Key Points

• Zacks Research has downgraded Exelixis from a "strong-buy" rating to a "hold" rating, indicating a shift in sentiment for the stock.
• Despite the downgrade, other analysts maintain a generally positive outlook, with thirteen ratings for Buy and a target price averaging $44.06.
• Exelixis reported earnings of $0.75 per share in its last quarter, surpassing expectations, but its quarterly revenue fell by 10.8% compared to the previous year.

Exelixis (NASDAQ:EXEL - Get Free Report) was downgraded by investment analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Exelixis' Q4 2025 earnings at $0.55 EPS and Q4 2026 earnings at $0.75 EPS.

Several other research analysts also recently commented on EXEL. Jefferies Financial Group set a $50.00 price objective on shares of Exelixis and gave the company a "buy" rating in a research report on Tuesday, June 24th. HC Wainwright cut their price target on shares of Exelixis from $53.00 to $46.00 and set a "buy" rating on the stock in a research report on Tuesday, August 12th. Stifel Nicolaus increased their price objective on shares of Exelixis from $38.00 to $41.00 and gave the stock a "hold" rating in a research report on Tuesday, July 29th. Stephens upgraded shares of Exelixis from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $29.00 to $60.00 in a report on Tuesday, June 24th. Finally, UBS Group set a $38.00 price objective on shares of Exelixis and gave the company a "neutral" rating in a research note on Wednesday, July 30th. Thirteen analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Exelixis presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.06.

Exelixis Stock Performance

Shares of NASDAQ EXEL traded down $0.48 during midday trading on Tuesday, reaching $37.42. The company's stock had a trading volume of 2,589,106 shares, compared to its average volume of 2,502,768. Exelixis has a fifty-two week low of $25.12 and a fifty-two week high of $49.62. The business's 50 day moving average price is $41.26 and its two-hundred day moving average price is $39.53. The company has a market cap of $10.07 billion, a P/E ratio of 17.99, a P/E/G ratio of 0.77 and a beta of 0.32.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same period in the previous year, the business earned $0.84 earnings per share. The firm's quarterly revenue was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Exelixis will post 2.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, Director Jack L. Wyszomierski sold 7,535 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total value of $324,683.15. Following the completion of the transaction, the director directly owned 358,882 shares of the company's stock, valued at $15,464,225.38. This trade represents a 2.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.82% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its stake in Exelixis by 32.2% in the first quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company's stock worth $201,000 after purchasing an additional 1,328 shares during the last quarter. Park Avenue Securities LLC increased its position in shares of Exelixis by 10.6% during the first quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company's stock valued at $272,000 after buying an additional 707 shares during the period. Envestnet Asset Management Inc. increased its position in shares of Exelixis by 23.9% during the first quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company's stock valued at $9,159,000 after buying an additional 47,845 shares during the period. Flagship Harbor Advisors LLC purchased a new stake in Exelixis in the first quarter worth about $233,000. Finally, Concurrent Investment Advisors LLC purchased a new stake in Exelixis in the first quarter worth about $457,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.